Nexus Surgical

Why is Nexus Surgical and Medicare Ltd falling/rising?

As of 01-Sep, Nexus Surgical and Medicare Ltd's stock price is rising, currently at 22.77 with a 9.47% increase. The stock has shown strong performance, reversing a decline and trading above moving averages, despite a significant drop in investor participation.

As of 01-Sep, Nexus Surgical and Medicare Ltd's stock price is rising, evidenced by a current price of 22.77, which reflects a change of 1.97 or 9.47% increase. The stock has shown strong performance over various periods, with a remarkable 25.04% increase over the past week, significantly outperforming the Sensex, which declined by 0.92% during the same timeframe. <BR><BR>Today's trading session has been particularly positive, as the stock opened with a gain of 2.4% and reached an intraday high of Rs 23.95, marking a 15.14% increase at its peak. Additionally, the stock has reversed its trend after two consecutive days of decline, indicating a potential recovery in investor sentiment. <BR><BR>Despite high volatility, with an intraday volatility of 6.07%, the stock is trading above its moving averages across multiple timeframes, suggesting a strong upward trend. However, it is important to note that there has been a significant drop in investor participation, with delivery volume falling by 68.19% compared to the 5-day average, which could indicate some caution among investors. Overall, the combination of recent gains, strong performance relative to the benchmark, and a trend reversal contributes to the rising stock price of Nexus Surgical and Medicare Ltd.

Who are in the management team of Nexus Surgical?

The management team of Nexus Surgical includes Ram Swaroop Mahadev Joshi (Whole Time Director & CFO), Pawan Choudhary (Executive Director), and independent non-executive directors Rajesh Sodhani, Avinash Kumar Ardawatia, and Neha Kailash Bhageria.

The management team of Nexus Surgical includes the following individuals:<BR><BR>1. **Ram Swaroop Mahadev Joshi** - Whole Time Director & CFO<BR>2. **Pawan Choudhary** - Executive Director<BR>3. **Rajesh Sodhani** - Independent Non-Executive Director<BR>4. **Avinash Kumar Ardawatia** - Independent Non-Executive Director<BR>5. **Neha Kailash Bhageria** - Independent Non-Executive Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Nexus Surgical do?

Nexus Surgical and Medicare Ltd, a micro-cap company established in 1992, trades in medical essentials and operates within the Non Banking Financial Company (NBFC) sector. As of June 2026, it reported net sales of 3 Cr and a market cap of INR 12 Cr.

Overview:<BR>Nexus Surgical and Medicare Ltd is engaged in the trading of medical essentials and operates within the Non Banking Financial Company (NBFC) industry, categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1992, Nexus Surgical and Medicare Ltd was formerly known as Nexus Commodities and Technologies Ltd. The company has transitioned from manufacturing and marketing consumer durables to its current focus on medical essentials. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 43.33% <BR>Price to Book: 6.59 <BR><BR>Contact Details:<BR>Address: Gala No 4 Saarthak Bldg No 1, Square Industrial Park Palghar Maharashtra : 401208 <BR>Email: nexuscom99@gmail.com <BR>Website: http://www.nexusmed.co.in

Who are the peers of the Nexus Surgical?

Nexus Surgical's peers include Krishna Capital, Econo Trade Indi, Blue Chip India, J J Finance Corp, Indergiri Fin., NPR Finance, Ashtasidhhi Ind, and Anna Infrastruct. Econo Trade Indi and J J Finance Corp show excellent management and capital structures, while J J Finance Corp leads in 1-year returns at 26.97%, compared to Nexus Surgical's 15.24%.

Peers: The peers of Nexus Surgical are Krishna Capital, Econo Trade Indi, Blue Chip India, J J Finance Corp, Indergiri Fin., NPR Finance, Ashtasidhhi Ind, Anna Infrastruct.<BR><BR>Quality Snapshot: Excellent management risk is observed at Econo Trade Indi, J J Finance Corp, Indergiri Fin., NPR Finance, Ashtasidhhi Ind, and Anna Infrastruct, while Below Average management risk is found at Krishna Capital, Blue Chip India, and the rest. Good growth is noted at Econo Trade Indi and Nexus Surgical, while Average growth is seen at J J Finance Corp and Ashtasidhhi Ind, and the rest show Below Average growth. Excellent capital structure is present at Econo Trade Indi, J J Finance Corp, Indergiri Fin., NPR Finance, Ashtasidhhi Ind, and Nexus Surgical, while Good capital structure is found at Anna Infrastruct, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is J J Finance Corp at 26.97%, while the lowest is NPR Finance at -25.50%. Nexus Surgical's 1-year return of 15.24% is higher than NPR Finance's but lower than J J Finance Corp's. Additionally, Indergiri Fin., NPR Finance, and Ashtasidhhi Ind have negative six-month returns.

How big is Nexus Surgical?

As of 31st August, Nexus Surgical and Medicare Ltd has a market capitalization of 12.00 Cr, with net sales of 8.70 Cr and net profit of 0.78 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Nexus Surgical and Medicare Ltd has a market capitalization of 12.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8.70 Cr, while the sum of Net Profit for the same period is 0.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 1.06 Cr, and Total Assets are valued at 2.27 Cr.

Which are the latest news on Nexus Surgical?

Should I buy, sell or hold Nexus Surgical and Medicare Ltd?

Are Nexus Surgical and Medicare Ltd latest results good or bad?

Nexus Surgical's latest results show strong profitability with a net profit increase of 41.18% quarter-over-quarter, but a concerning 30.03% decline in net sales raises questions about revenue stability. Investors should be cautious and monitor the company's ability to stabilize its revenue streams.

Nexus Surgical's latest results present a mixed picture. On one hand, the company achieved a net profit of ₹0.24 crores in Q4 FY26, which is a significant improvement of 41.18% compared to the previous quarter and a remarkable 166.67% increase year-on-year. This indicates strong profitability growth and improved operational efficiency, as evidenced by a PAT margin that rose to 11.71%.<BR><BR>However, the net sales for the same quarter saw a substantial decline of 30.03% compared to the previous quarter, dropping to ₹2.05 crores. While this represents a year-on-year increase of 38.51%, the sequential drop highlights volatility in revenue generation, which is a concern for the company's stability.<BR><BR>Overall, while the profitability metrics are encouraging, the erratic nature of revenue growth raises questions about the sustainability of this performance. Investors should be cautious and monitor whether the company can stabilize its revenue streams moving forward.

When is the next results date for Nexus Surgical and Medicare Ltd?

The next results date for Nexus Surgical and Medicare Ltd is 14 February 2026.

The next results date for Nexus Surgical and Medicare Ltd is scheduled for 14 February 2026.

How has been the historical performance of Nexus Surgical?

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.

Answer:<BR>The historical performance of Nexus Surgical shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Nexus Surgical's net sales have increased from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, indicating strong growth. Total operating income followed a similar trend, rising from 1.55 Cr in March 2023 to 5.72 Cr in March 2025. The company's total expenditure also grew, reaching 5.06 Cr in March 2025, up from 1.34 Cr in March 2023. Despite this increase, the operating profit (PBDIT) improved from 0.21 Cr in March 2023 to 0.67 Cr in March 2025, reflecting a healthier operating profit margin of 11.54% in March 2025 compared to 13.55% in March 2023. Profit before tax also rose from 0.23 Cr in March 2023 to 0.67 Cr in March 2025, with profit after tax increasing from 0.17 Cr to 0.50 Cr over the same period. The earnings per share (EPS) improved significantly from 0.31 in March 2023 to 0.91 in March 2025. On the balance sheet, total assets increased from 0.91 Cr in March 2023 to 2.27 Cr in March 2025, while total liabilities rose from 0.91 Cr to 2.27 Cr in the same timeframe. The company has maintained zero debt throughout this period. Overall, Nexus Surgical's financial performance demonstrates a positive trajectory in sales, profitability, and asset growth.

Who are the top shareholders of the Nexus Surgical?

The top shareholders of Nexus Surgical are Mildred Mercantile Private Limited with 18.55%, Harivardhan Steel & Alloys Private Limited at 16.01%, and individual investors holding a combined 44.64%. There are no institutional holdings in the company.

The top shareholders of Nexus Surgical include Mildred Mercantile Private Limited, which holds the highest promoter stake at 18.55%. The next significant public shareholder is Harivardhan Steel & Alloys Private Limited, with a holding of 16.01%. Additionally, individual investors collectively hold 44.64% of the company's shares. There are no institutional holdings reported, as mutual funds and foreign institutional investors do not hold any shares in Nexus Surgical.

Is Nexus Surgical overvalued or undervalued?

As of November 15, 2023, Nexus Surgical is considered very expensive and overvalued with a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a high ROE of 47.17%, but it has underperformed the Sensex by 37.39% year-to-date.

As of 15 November 2023, Nexus Surgical's valuation grade has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a ROE of 47.17%. These figures suggest that while the company has a high return on equity, its valuation metrics are not compelling when compared to peers.<BR><BR>In comparison to its industry peers, Nexus Surgical's PE ratio of 9.23 is lower than Life Insurance's PE of 12.54, but significantly higher than Bajaj Finance's PE of 35.01, which is categorized as very expensive. The PEG ratio of 0.07 also highlights that the stock may not be justified at its current price given its growth prospects. Additionally, Nexus Surgical has underperformed the Sensex over various time frames, particularly year-to-date, where it has declined by 37.39% compared to the Sensex's gain of 5.59%.

What is the technical trend for Nexus Surgical?

As of June 4, 2025, Nexus Surgical's trend is mildly bearish due to daily moving averages, despite mixed signals from weekly and monthly indicators, with the stock down 6.39% over the past week.

As of 4 June 2025, the technical trend for Nexus Surgical has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD and KST are mildly bullish, but the monthly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, but this is overshadowed by the bearish daily moving averages. Overall, the strength of the bearish trend is supported by the recent price action, with the stock down 6.39% over the past week, contrasting with a positive return from the Sensex.

Has Nexus Surgical declared dividend?

No Dividend History Available